These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 15500133

  • 1. [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].
    Takeda Y, Tomino Y.
    Nihon Rinsho; 2004 Oct; 62(10):1875-9. PubMed ID: 15500133
    [Abstract] [Full Text] [Related]

  • 2. [Immunosuppressive therapies for refractory nephrotic syndrome].
    Mitarai T.
    Nihon Jinzo Gakkai Shi; 2010 Oct; 52(7):924-7. PubMed ID: 21077342
    [No Abstract] [Full Text] [Related]

  • 3. [Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].
    Nishikido M, Kanekake H, Harada T.
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():634-8. PubMed ID: 16523968
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
    Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
    [Abstract] [Full Text] [Related]

  • 5. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.
    Loeffler K, Gowrishankar M, Yiu V.
    Pediatr Nephrol; 2004 Mar; 19(3):281-7. PubMed ID: 14758528
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
    Bagga A, Hari P, Moudgil A, Jordan SC.
    Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
    [Abstract] [Full Text] [Related]

  • 7. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A, Stec Z, Pełkowska A, Sancewicz-Pach K, Pietrzyk JA.
    Przegl Lek; 2006 Dec; 63 Suppl 3():44-8. PubMed ID: 16898486
    [Abstract] [Full Text] [Related]

  • 8. Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome.
    Mizutani A, Fujinaga S, Sakuraya K, Hirano D, Shimizu T.
    Clin Exp Nephrol; 2019 Feb; 23(2):244-250. PubMed ID: 30121800
    [Abstract] [Full Text] [Related]

  • 9. [Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis].
    Dudzik B, Kaczmarczyk I, Radziszewski A, Sułowicz W.
    Przegl Lek; 2001 Feb; 58(7-8):798-804. PubMed ID: 11769390
    [Abstract] [Full Text] [Related]

  • 10. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
    Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, Gu W, Shu Q, Du L.
    Nephrology (Carlton); 2015 Jan; 20(1):18-24. PubMed ID: 25312783
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A.
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [Abstract] [Full Text] [Related]

  • 12. Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis.
    Kuhn C, Kuhn A, Markau S, Kästner U, Osten B.
    J Clin Apher; 2006 Dec; 21(4):266-70. PubMed ID: 17120233
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of steroid-resistant polymyositis and dermatomyositis].
    Mimura T, Kanda H, Kubo K.
    Nihon Rinsho; 2001 Oct; 59(10):2062-70. PubMed ID: 11676154
    [Abstract] [Full Text] [Related]

  • 14. Failure of mycophenolate mofetil therapy in primary refractory nephrotic syndrome.
    Baglio V, Pecci G, Gangemi C, Barresi G, Morabito S, Pierucci A.
    J Nephrol; 2006 Oct; 19(6):819-24. PubMed ID: 17173257
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome.
    Tasanarong A, Thitiarchakul S.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S218-27. PubMed ID: 17044475
    [Abstract] [Full Text] [Related]

  • 16. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
    Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, Bagga A.
    Kidney Int; 2012 Nov; 82(10):1130-5. PubMed ID: 22763815
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
    Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, Perkovic V, Hong D.
    PLoS One; 2017 Jul; 12(9):e0184398. PubMed ID: 28898290
    [Abstract] [Full Text] [Related]

  • 19. [Immunosuppressants for therapy of patients with ulcerative colitis].
    Hisamatsu T, Hibi T.
    Nihon Rinsho; 2005 May; 63(5):831-5. PubMed ID: 15881178
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.
    Moudgil A, Bagga A, Jordan SC.
    Pediatr Nephrol; 2005 Oct; 20(10):1376-81. PubMed ID: 15977023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.